THE FUTURE OF GENE THERAPY
AT A GLANCE
aratinga.bio is a preclinical-stage immunotherapy biotech company founded in March 2017 developing novel immunotherapies to treat cancer.
We want to harness the immune system to target and kill cancer cells.
To address unmet medical needs, aratinga.bio is developing its proprietary CAR T-cell platform effective against both hematological cancers and solid tumors regardless of the type of previous treatments patients have experienced.
The lentivector - encoding for the Chimeric Antigen Receptor - is coated with a polymeric envelope. The anti-CD3 targeting moiety grafted at the surface of the polymer directs the synthetic vector towards the T-cells.
aratinga.bio's in vivo technology does not require costly dedicated manufacturing sites to produce modified T-cells in contrast to approved ex vivo CAR T-cell therapies.
The genetic modification to express the CAR is directly generated in the patient.
CAR-T & BEYOND
aratinga.bio's CAR-T platform, represents a welcomed advantage over current recently approved ex vivo CAR-T therapies turning them into more effective, more universal, and safer treatments.
The encapsulation technology goes way beyond CAR-T, and includes gene therapy applications.
Thanks to the technology (a synthetic gene delivery platform), one can target any kind of cells as long as you can identify or screen for the corresponding specific receptor.
aratinga.bio is led by three founders with complementary experience and skills, with the common ambition of revolutionizing medicine through developing cutting-edge gene therapy-based treatments
Based in Paris and in New York. Worldwide connected
430 E 29th St 14th Floor, New York, NY 10016
France Office (headquarter)
1 mail du Professeur Georges Mathé - 94800 Villejuif